Network-of-1500-stroke-ready-clinics-across-Europe
Network of 1,500 stroke-ready clinics across Europe  The award-winning Angels Initiative delivers on its three-year goal to create a network of more than 1,500 stroke-ready clinics across EuropeSince 2016, a total of 2,700 clinics worldwide are now part of the Angels InitiativeThe ESO Angels Awards praise 331 clinics in several countries who have made great steps in optimising stroke care for patients locally (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2019 Category: Research Source Type: news

nintedanib slows pulmonary function loss in people with ssc-ild
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1Results of pivotal Phase III SENSCIS ®trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USAInterstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3FDA grants priority review to application for regulatory approval for nintedanib in patients ...
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news

Veterinary oncology experts meet in Germany
Veterinary oncology experts from Europe, Japan and the US meet in GermanyVeterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, GermanyThe collaboration between Boehringer Ingelheim and the Veterinary Oncology Advisory Board focuses on developing unparalleled therapeutic solutions for the veterinary community and establishing new standards of care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news

NOAC-vs-ASA-in-ESUS-trial-results-published-in-NEJM
Trial results of Pradaxa ® vs ASA in ESUS published in NEJMFirst Phase III randomised clinical trial to compare dabigatran etexilate and acetylsalicylic acid (ASA)  No significant difference in recurrent stroke prevention after ESUSDabigatran showed no significant difference in major bleeding (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 16, 2019 Category: Research Source Type: news

Boehringer Ingelheim fosters cooperation with innovative partners
Digital transformation: Boehringer Ingelheim fosters cooperation with innovative partnersDigital technologies can contribute to improved monitoring, more rapid diagnosis, and more successful treatmentPilot project with Belgian start-up SoundTalks facilitates disease prevention among farm animals  Open innovation online portal promotes collaboration with external partners in research and development   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 14, 2019 Category: Research Source Type: news

Accelerator_program_mmh
Boehringer Ingelheim announces finalists of the Making More Health Accelerator ProgramBoehringer Ingelheim to support scale up of two projects of its Making More Health (MMH) Accelerator Program.The Accelerator Program aims to help early stage enterprises develop sustainable care delivery models. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 2, 2019 Category: Research Source Type: news

annual_results_press_conference_2019
Financial year 2018:  Boehringer Ingelheim grows and invests Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseasesOperating growth outpaces the market in all businessesTechnical integration of the animal health business acquired in 2017 successfully completed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 16, 2019 Category: Research Source Type: news

Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme Boehringer Ingelheim plans a pilot programme using the innovative SoundTalksTM system in select pig barnsThe goal is to harness the power of digital innovation and technological change to detect possible respiratory distress in swine quickly (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

Real-world-study-comparing-NOACs-in-AF-patients
Independent large real-world study comparing NOACs in AF-patientsA recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1  Results of the real-world study showed that Pradaxa ® (dabigatran etexilate) was associated with a more favourable benefit-risk profile in comparison to both warfarin and rivaroxaban1Data from an earlier FDA-funded Medicare study published in 2015, which investigated cardiovascular, bleeding and mortality risks among patients...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes
New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1  Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabeti...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

Celebrating 20 years of Metacam for cattle
Boehringer Ingelheim celebrates 20 years of Metacam ® for cattle2019 marks the anniversary of Metacam ® (meloxicam) for cattleOriginally licenced for dogs, Metacam ®can be used in other species to treat inflammatory and painful conditionsBoehringer Ingelheim celebrates this 20-year milestone since pioneering meloxicam for use in both humans and animals (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news

Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and DortmundEuropean launches of next-generation inhaler kicked off  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news

Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicineEuropean Commission has granted marketing authorisation for the first stem cell-based product in animal healthArti-Cell ® Forte is a unique ready-to-use solution for the treatment of equine lamenessThe partnership of Boehringer Ingelheim and GST proves its commitment to bring highly innovative therapeutics for horses to customers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 7, 2019 Category: Research Source Type: news

‘uniqueness’ by championing both human and animal health
Boehringer Ingelheim celebrates its ‘uniqueness’ by championing both human and animal health in new campaign Boehringer Ingelheim changes perception due to its dedication to human and animal health“A Unique Bond” explores stories of the positive impact animals can have on patient’s lives  Launched in 28 countries, the company affirms its dedication to both human and animal health with local initiatives   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2019 Category: Research Source Type: news

Positivity... just a paw away
Positivity … just a paw awayOwners claim that their pet has a strong positive impact on their daily lives.1   According to experts, “pets benefit the lives of their owners, both psychologically and physically”.2 Acknowledging this, Boehringer Ingelheim launches global initiatives to improve the positivity of their employees, patients and animals alike. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2019 Category: Research Source Type: news

Why we may be more like our pets than we think
Like their owners, pets are living longer1  and are prone to conditions such as cancer and obesity.2,3,4Recent data exploring the human-animal connection shows that pets are integral to improving our quality of life.5A global campaign reveals the remarkable bond between people and animals, and how pets can help provide support through illness as well as recovery.6   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 2, 2019 Category: Research Source Type: news

Launch of BVDzero scholarship for veterinary students
Boehringer Ingelheim launches BVDzero scholarship for veterinary students globallyBoehringer Ingelheim grants a total BVDzero scholarship of 10,000 euro to top 10 students worldwideThe company  aims to increase bovine viral diarrhea (BVD) awareness among veterinary studentsThis initiative is implemented in collaboration with the World Association for Buiatrics, as an incentive to participate in the World Buiatrics Congress 2020 in Madrid    (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production siteThe acquisition includes the Saint-Herblon production site and the Coophavet brandThe sale is part of the Boehringer Ingelheim ’s strategic refocusing on advanced and preventive animal healthcare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

Acquisition of novel oncology delivery technology
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD TherapeuticsNew molecular platform to access intracellular targets across a broad range of tumor cell typesOpens up new range of therapeutic opportunities for difficult-to-treat cancers   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019  EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initia...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news

World water day 2019
World Water Day - Making every drop countBoehringer Ingelheim started a social project in Mexico City to preserve the aquifer and to ensure the water supply for dog shelters  First rainwater collector and filter will save 180,000 liters of rainwater every yearPublic campaign also promotes sterilization and adoption of   shelter dogs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2019 Category: Research Source Type: news

FDA-and-EMA-regulatory-submission-nintedanib-in-SSc-ILD
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILDSystemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue diseasePulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 15, 2019 Category: Research Source Type: news

NEJM-IL-36-Phase-1-GPP-data
Novel antibody shows potential to transform treatment of rare form of psoriasisPublished in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 6, 2019 Category: Research Source Type: news

Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline Flagship Store on TmallBoehringer Ingelheim launches its flagship store on an e-commerce platform TmallThe store specialises on the company ’s full range of pet parasiticidesBoehringer Ingelheim recognises e-commerce as paramount for its growth in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 27, 2019 Category: Research Source Type: news

Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics developmentProgramme could lead to new diagnostic solutions for African swine feverBoehringer Ingelheim demonstrates its focus on prevention and innovation yet again (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 22, 2019 Category: Research Source Type: news

New Chief Medical Officer appointed
  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 22, 2019 Category: Research Source Type: news

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Blockchain technology has the potential to improve trust, transparency, patient safety and patient empowerment in clinical trials (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 12, 2019 Category: Research Source Type: news

CAROLINA-top-line
For non-US, non-UK audiences (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2019 Category: Research Source Type: news

Boehringer Ingelheim leader in hatchery vaccination with vector vaccines
Boehringer Ingelheim reaffirms its leading position in hatchery vaccination with its vector vaccines at IPPE 2019Vaxxitek ® HVT + IBD continues to lead in hatchery vector vaccination worldwideNewxxitek ® HVT + ND is Boehringer Ingelheim’s latest vectored vaccine against Newcastle disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2019 Category: Research Source Type: news

Launch of first veterinary vaccines produced in China
Boehringer Ingelheim launches first veterinary vaccines produced in ChinaThe first local manufacturing plant, wholly-owned by a multinational animal health company, focuses on the China swine marketThe Taizhou plant will produce PRRS vaccines and supply them locallyThe company delivers on its long-term ‘in China, for China’ commitment while accelerating its localisation strategy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 24, 2019 Category: Research Source Type: news

Boehringer_ingelheim_partners_with_ampath_in_Kenya
Boehringer Ingelheim partners with AMPATH to scale up knowledge, skills and training for healthcare providers in KenyaPartnership with AMPATH aims to advance Boehringer Ingelheim ’s Healthcare Initiative In Reach Africa Collaboration partnership to build a holistic and sustainable health system in Kenya  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 23, 2019 Category: Research Source Type: news

A_Healthy_2019
A healthy 2019: Four paws for more relaxation and exerciseAn international study confirms that the emotional bonds between people and their pets enhance health and well-beingOver 90 percent of pet owners say their animals have a positive effect on their quality of lifePets also help people stick to their New Year ’s resolutions  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 21, 2019 Category: Research Source Type: news

Capacity_expansion_OASIS
Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacitiesExpansion of manufacturing capacities in OASIS facilityIncreasing demands for world-class manufacturing in Shanghai, ChinaFirst commercial product manufacturing in Shanghai expected in 2019  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 17, 2019 Category: Research Source Type: news

Second Dicerna Hepatic Disease Target Option Exercise
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target  From Research Collaboration with Dicerna Collaboration seeks to develop novel treatments for chronic liver diseases,  including nonalcoholic steatohepatitis (NASH)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 4, 2019 Category: Research Source Type: news

Collaboration with Vanderbilt University
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders  Boehringer Ingelheim Enhances Central Nervous System Disease PipelineVanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Virtual clinical trial collaboration with Science 37
Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies  Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide  Science 37 ’s technology enables patients to remotely participate in clinical studies, which enables increased patient diversity, study efficiency and speed, while decreasing patient burden (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Inauguration_facility_children_with_multiple_disabilities
Boehringer Ingelheim and the Muskan Foundation inaugurate facility for children with multiple disabilities  New Facility is'first-of-its-kind'at B.J. Wadia Children ’s Hospital, Disability Centre in Mumbai, India Special educational programs will train children with Multiple Disabilities with Visual Impairment (MDVI)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 17, 2018 Category: Research Source Type: news

A tool to aid in the prevention of African swine fever
Boehringer Ingelheim launches a tool to aid in the prevention of African swine feverASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever (ASF) introduction risk levelBoehringer Ingelheim reconfirms its commitment to developing new innovative solutions to address current challenges   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 14, 2018 Category: Research Source Type: news

VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1  support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news

Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK since 2006
Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK ® HVT + IBD since 2006VAXXITEK ® HVT + IBD provides a life-long immunity against Infectious bursal disease and Marek's diseaseIt is the first vector vaccine to have been launched on the avian marketVAXXITEK ® HVT + IBD is registered in more than 75 countries  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 12, 2018 Category: Research Source Type: news

Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine marketFirst-ever veterinary stem cell medicine recommended for EU marketing authorisationArti-Cell Forte provides a unique ready-to-use solution for the treatment of equine lamenessBoehringer Ingelheim again demonstrates its commitment to continuous innovation  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2018 Category: Research Source Type: news

LastMile initiative to address barriers in animal healthcare
Boehringer Ingelheim launches ‘LastMile’ initiative to address major barriers in animal healthcare sector in Sub-Saharan AfricaThe initiative is established by Boehringer Ingelheim and supported by GALVmed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 3, 2018 Category: Research Source Type: news

Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim announces two new claims for Nexgard ® and Nexgard Spectra® in the EU and AustraliaBoehringer Ingelheim expands the label claims of its NexGard ® brands for the treatment of two severe skin diseases in dogs in the EU and in AustraliaBy broadening the range, Boehringer Ingelheim contributes to the improvement of dogs ’ health globally (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Empa ACC Expert Consensus Decision Pathway
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partners with Ipsos to gain insights on human-animal bond in EuropeThe human-animal bond survey assigned to the global Research Institute Ipsos took place in 2017 in five European countries, targeting 3,000 pet ownersThe survey results show a strong positive impact of pet relationship on owners'well-beingVeterinarians prove to be the contact of choice to provide information on the topic (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 21, 2018 Category: Research Source Type: news

Epizyme_Collaboration
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies  Boehringer Ingelheim Expands Biomarker-driven Oncology Programs   Alliance Enhances Epizyme ’s Leadership in Oncology Epigenetics  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 15, 2018 Category: Research Source Type: news

Official partner to Cat Care for Life
Boehringer Ingelheim becomes an official partner to CatCareforLifeTheCatCareforLife program is a new worldwide initiative set up by the International Society of Feline MedicineIt aims to encourage cat owners to work with their veterinary clinics to maintain cats in the peak of health through all their life stagesBoehringer Ingelheim is committed to further improving the health and well-being of cats and helping educate veterinarians and cat owners (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Extension_BioXcellence_Fremont
Boehringer Ingelheim achieves next expansion milestone in biologics production in the USCulmination of a €200 million investment in CaliforniaWorldwide capacity for manufacturing biopharmaceutical medicines now exceeds 290,000 litersGlobal manufacturing network for products in Boehringer Ingelheim ’s own research pipeline and for contract manufacturing (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 30, 2018 Category: Research Source Type: news

New working environment for agile working methods
Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animalsNew building inaugurated exclusively for agile working methods in IngelheimAgile Facilitators strengthen Boehringer Ingelheim from ideation to development of scalable solutions for human and animal health  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 25, 2018 Category: Research Source Type: news